13.10.2015 • News

Teva Launches Generic Dutasteride

Israeli generics giant Teva Pharmaceutical Industries has launched a generic equivalent to Glaxo SmithKline’s Avodart (dutasteride) 0.5 mg capsules on the US market.

The active ingredient dutasteride, a 5 alpha-reductase enzyme inhibitor, works by lowering production of the hormone dihydrotestosterone (DHT and is used to treat the symptoms of benign prostatic hyperplasia (BPH) in men with an enlarged prostate.

First drugmaker to file for a generic application, Teva said it expects its product to be exclusive for several weeks. GlaxoSmithKline has annual sales of about $467 million from the capsules.

 

 

Interview

Driving Sustainability Through Collaboration
Building Green Practices Across the Chemical Supply Chain

Driving Sustainability Through Collaboration

Together for Sustainability (TfS) is a pioneering, member-led initiative working to accelerate sustainable and resilient chemical supply chains. TfS President Jennifer Jewson discusses the origins of TfS, its evolving goals, its present-day challenges, and the initiative’s enduring impact and outlook for the future.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

Top-Feature

most read